A Tamer 'Wildcard'? Antibiotic Exclusivity Would Have More Strings Attached In New Bill
Executive Summary
Advocates for antibiotic incentives are hoping to attach 'wildcard' patent proposal to pending PAHPA reauthorization bill; New conditions on exclusivity are intended to make approach more politically viable – and assure favorable CBO score.
You may also be interested in...
Pharma Welcomes UK Incentive Plan To Tackle AMR
There has been an enthusiastic response from industry to the news that NICE and NHS England are to explore a new payment model that pays pharmaceutical companies based on how valuable their medicines are to the country's health service, rather than on the quantity of antibiotics sold.
Biodefense Bill Moving In Senate; Still Debate Over Best Approach For Flu
US Pandemic and All Hazards Preparedness Act appears on track for on-time reauthorization – but there may still be debate over whether and how to dedicate funding specifically for pandemic flu preparedness and stockpiling.
‘Wildcard’ Patents: Why A REVAMP-ed Proposal Might Work In 2017
Before election day, the idea of a new transferrable exclusivity incentive seemed like an extreme long shot for enactment. But now advocates think it has a real chance – and a strategy to redraft the idea to answer Democratic critics and avoid a high CBO score.